Abstracts tagged "Epidemiology"

Abstract Number: 1754 • ACR Convergence 2020
The Point of No Return? Functional Disability in Patients with Rheumatoid Arthritis versus the General Population: Results from a Population-based Cohort Study
Elena Myasoedova¹, John Davis¹, Vanessa Kronzer¹, Rachel Giblon¹, Elizabeth Atkinson¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Despite the advances in treatment of rheumatoid arthritis (RA), many patients do not achieve remission or full physical functioning. We have previously shown that…
Abstract Number: 0274 • ACR Convergence 2020
The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades
Mehmet Hocaoglu¹, Shirley-Ann Osei-Onomah², Jesse Dabit³, Rachel Giblon³, Thomas O'Byrne³, Fernando C. Fervenza³, Cynthia Crowson⁴ and Ali Duarte-Garcia³, ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Estimating the incidence of lupus nephritis (LN) is important to understand disease burden, particularly since patients with LN have a higher morbidity and mortality…
Abstract Number: 0554 • ACR Convergence 2020
Increased Burden of Painful Arthritis and Rheumatism Following the Chikungunya Epidemic 2006: India Rural Population Survey 2018
Arvind Chopra¹, Ravi Ghorpade², Anuradha Venugopalan¹, Manjit Saluja¹ and Kiran Adam¹, ¹Center for Rheumatic Diseases, Pune, India, ²Center for Rheumatic Diseases, Pune
Background/Purpose: A spectrum of post Chikungunya (Chik) arthritis , often RA like, were referred to an urban rheumatology centre (Pune India)during the 2006 epidemic (Arthritis…
Abstract Number: 0815 • ACR Convergence 2020
Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients
Deepan Dalal¹, Tingting Zhang², Hiren Varma² and Theresa Shireman², ¹Brown University, East Providence, RI, ²Brown University, Providence, RI
Background/Purpose: Methotrexate is the preferred initial drug for treatment of rheumatoid arthritis (RA) per American College of Rheumatology guidelines (2015). People with elderly-onset RA, classified as onset…
Abstract Number: 1023 • ACR Convergence 2020
Epidemiology and Sociodemographic Distribution of Upper Gastrointestinal Bleeding Among Medicaid Beneficiaries with Systemic Lupus Erythematosus
Chang Xu¹, Molly Perencevich², Seoyoung Kim², Karen Costenbader³ and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have multiple risk factors for upper gastrointestinal bleeding (UGIB), including heightened susceptibility to infection and glucocorticoid, NSAID and…
Abstract Number: 1140 • ACR Convergence 2020
How Did SARS-CoV2/COVID-19 Pandemic Affected Patients with Rheumatic Diseases in Latin America? A Regional Survey from PANLAR
Daniel Fernández-Ávila¹, Julián Barahona-Correa¹, Diana Romero-Alvernia¹, Sergio Kowalski², Ana María Sapag Durán³, Antonio Cachafeiro Vilar⁴, Belia Lucía Meléndez Muñoz⁵, Carlos Santiago Pastelín⁶, Claudia Ramírez⁷, Daniel Palleiro Rivero⁸, Diego Alejandro Jaimes⁹, Dina María Arrieta¹⁰, Guillermo Pons-Estel¹¹, Jossiell Then Báez¹², Manuel Ugarte-Gil¹³, Mario Cardiel¹⁴, Nelly Colman¹⁵, Nilmo Chávez Pérez¹⁶, Paula Burgos¹⁷, Rubén Montufar¹⁸, Sayonara Sandino¹⁹, Yurilis Fuentes-Silva²⁰ and Enrique Soriano²¹, ¹Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogota, Colombia, ²Unidad de Investigación PANLAR. Universidade Federal do Paraná, Paraná, Brazil, ³Hospital Universitario Japonés, Santa Cruz, Bolivia, ⁴Pacífica Salud - Hospital Punta Pacífica,, Ciudad de Panamá, Panama, ⁵Hospital de la Policía Nacional N1 Quito, Quito, Ecuador, ⁶Instituto Hondureño de la Seguridad Social, Tegucigalpa, Honduras, ⁷Organización Keralty, Bogota, ⁸Instituto Nacional de Reumatología del Uruguay - Universidad de la República, Montevideo, Uruguay, ⁹Clínicos IPS- Universidad de la Sabana, Bogotá D.C., Colombia, ¹⁰Hospital México, San José de Costa Rica, Costa Rica, ¹¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹²Hospital Metropolitano de Santiago (HOMS), Santiago, Dominican Republic, ¹³Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen and Universidad Científica del Sur, Lima, Peru, ¹⁴Centro de Investigación Clínica de Morelia, Morelia, Mexico, ¹⁵Hospital de Clínicas - Universidad Nacional de Asunción, Asunción, Paraguay, ¹⁶Instituto Guatemalteco de Seguridad Social, Ciudad de Guatemala, Guatemala, ¹⁷Universidad Católica de Chile, Santiago de Chile, Chile, ¹⁸Consultorio de Especialidades del Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador, ¹⁹Policlínica Nicaragüense, Managua, Nicaragua, ²⁰Centro Clínico Universitario de Oriente - Universidad de Oriente, Ciudad Bolivar, Venezuela, ²¹Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina
Background/Purpose: Social isolation during SARS-CoV-2/COVID-19 pandemic has undermined follow-up of patients with rheumatic diseases. These patients face a critical dilemma between the risk of exposure…
Abstract Number: 1475 • ACR Convergence 2020
Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the US: A Nationwide Study
Rayan Najjar¹, Swetha Ann Alexander², Grant Hughes¹, Jinoos Yazdany³ and Namrata Singh⁴, ¹University of Washington, Seattle, WA, ²University of Connecticut, Hartford, CT, ³UCSF, San Francisco, CA, ⁴University of Washington, Bellevue, WA
Background/Purpose: For individuals with systemic lupus erythematosus (SLE), hospital readmission rate is associated with quality of care and prognosis. Our objective was to evaluate independent…
Abstract Number: 1841 • ACR Convergence 2020
Outcomes After Hydroxychloroquine Reduction or Discontinuation in a Multinational Inception Cohort of Systemic Lupus
Celline Almeida-Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen M Ginzler⁸, Daniel J Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Mary Ann Dooley¹², Christine A. Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁴, Susan Manzi¹⁵, Søren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald Van Vollenhoven¹⁸, Ola Nived¹⁹, Andreas Jönsen¹⁹, Diane Kamen²⁰, Cynthia Aranow²¹, Guillermo Ruiz-Irastorza²², Jorge Sanchez-Guerrero²³, Dafna Gladman²⁴, Paul Fortin²⁵, Graciela Alarcón²⁶, Joan Merrill²⁷, Kenneth Kalunian²⁸, Manuel Ramos-Casals²⁹, Kristjan Steinsson³⁰, Asad Zoma³¹, Anca Askanase³², Munther Khamashta³³, Ian Bruce³⁴, Murat Inanc³⁵ and Sasha Bernatsky³⁶, ¹McGill University, Montreal, Canada, ²QEII Health Sciences Centre, Halifax, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Calgary, Calgary, Canada, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, ⁸SUNY Downstate Health Sciences University, Brooklyn, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Salvador Zubirán National Institute of Health Sciences and Nutrition, Mexico City, Mexico, ¹²UNC Health, Chapel Hil, ¹³University of Manitoba, Winnipeg, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Temple University, Philadelphia, ¹⁶University of Copenhagen, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸University of Amsterdam, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²Hospital Universitario Cruces, Bizkaia, Spain, ²³University of Toronto, Toronto, Canada, ²⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁵CHU de Quebec - Universite Laval, Quebec, Canada, ²⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁷New York University, New York, ²⁸University of California San Diego, La Jolla, CA, ²⁹University of Barcelona, Barcelona, Spain, ³⁰Reykjavik University, Reykjavik, Iceland, ³¹University of Glasgow, Glasgow, United Kingdom, ³²Columbia University College of Physicians & Surgeons, New York, NY, ³³King's College London, London, United Kingdom, ³⁴The University of Manchester, Manchester, United Kingdom, ³⁵Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone treatment for several autoimmune diseases including Systemic Lupus Erythematosus (SLE). Recently, concerns arose regarding HCQ shortages for SLE patients,…
Abstract Number: 0278 • ACR Convergence 2020
Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study
Mehmet Hocaoglu¹, Mark Denis P. Davis², Shirley-Ann Osei-Onomah³, Jesse Dabit², Rachel Giblon², Thomas O'Byrne², Cynthia Crowson⁴ and Ali Duarte-Garcia², ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous chronic disease with potential for long lasting morbidity. Studies that provide incidence data on the entire spectrum…
Abstract Number: 0555 • ACR Convergence 2020
Utilization and Adherence Among Infliximab Biosimilar Initiators in a U.S. National Commercial Insurance Database
Sujith Sarvesh¹, Joseph Alanaeme¹, Jeffrey R Curtis² and Huifeng Yun², ¹University of Alabama at Birmingham, BIrmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Infliximab Biosimilar, the first biosimilar to infliximab, was approved for multiple indications in the U.S. in 2016. Since the utilization of biosimilar in the…
Abstract Number: 0869 • ACR Convergence 2020
Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine
Celline Almeida-Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen M Ginzler⁸, Daniel J Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Díaz¹¹, Mary Ann Dooley¹², Christine A. Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁴, Susan Manzi¹⁵, Søren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald Van Vollenhoven¹⁸, Ola Nived¹⁹, Andreas Jönsen¹⁹, Diane Kamen²⁰, Cynthia Aranow²¹, Guillermo Ruiz-Irastorza²², Jorge Sanchez-Guerrero²³, Dafna Gladman²⁴, Paul Fortin²⁵, Graciela Alarcón²⁶, Joan Merrill²⁷, Kenneth Kalunian²⁸, Manuel Ramos-Casals²⁹, Kristjan Steinsson³⁰, Asad Zoma³¹, Anca Askanase³², Munther Khamashta³³, Ian Bruce³⁴, Murat Inanc³⁵ and Sasha Bernatsky³⁶, ¹McGill University, Montreal, Canada, ²QEII Health Sciences Centre, Halifax, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Calgary, Calgary, Canada, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, ⁸SUNY Downstate Health Sciences University, Brooklyn, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²UNC Health, Chapel Hil, ¹³University of Manitoba, Winnipeg, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Temple University, Philadelphia, ¹⁶University of Copenhagen, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸University of Amsterdam, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²Hospital Universitario Cruces, Barakaldo, Spain, ²³University of Toronto, Toronto, Canada, ²⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁵CHU de Quebec - Universite Laval, Quebec, Canada, ²⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁷New York University, New York, ²⁸University of California San Diego, La Jolla, CA, ²⁹University of Barcelona, Barcelona, Spain, ³⁰Reykjavik University, Reykjavik, Iceland, ³¹University of Glasgow, Glasgow, United Kingdom, ³²Columbia University College of Physicians & Surgeons, New York, NY, ³³King's College London, London, United Kingdom, ³⁴The University of Manchester, Manchester, United Kingdom, ³⁵Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Despite the beneficial effects of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE), retinal toxicity is a concern. Factors associated with retinal toxicity have been…
Abstract Number: 1024 • ACR Convergence 2020
Time Trends in the Incidence of Systemic Lupus Erythematosus: A 40-Year Study
Ali Duarte-Garcia¹, Mehmet Hocaoglu², Shirley-Ann Osei-Onomah³, Jesse Dabit¹, Rachel Giblon¹ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Changes over time in the incidence of Systemic Lupus Erythematosus (SLE) remain uncertain. It is unclear if the variations in established SLE risk factors,…
Abstract Number: 1198 • ACR Convergence 2020
Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis
Vanessa Kronzer¹, Weixing Huang², Paul Dellaripa³, Sicong Huang⁴, Vivi Feathers², Bing Lu⁵, Christine Iannaccone⁶, Ritu Gill⁷, Hiroto Hatabu⁸, Mizuki Nishino⁸, Cynthia Crowson⁹, John Davis¹, Michael Weinblatt⁴, Nancy Shadick¹⁰, Tracy J. Doyle¹¹ and Jeffrey Sparks¹⁰, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁶Division of General Internal Medicine; Brigham and Women’s Hospital, Topsfield, MA, ⁷Department of Radiology; Harvard Medical School, Beth Israel Deaconess Medical Center, Topsfield, MA, ⁸Department of Radiology; Brigham and Women’s Hospital, Boston, ⁹Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ¹⁰Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Despite the known excess mortality of rheumatoid arthritis-associated interstitial lung disease (RA-ILD), its association with certain lifestyle factors such as obesity and future prediction…
Abstract Number: 1476 • ACR Convergence 2020
Trends in Mortality and Cause-specific Mortality Among Patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada
Keith Colaco¹, Jessica Widdifield², Jin Luo³, Cheryl Rosen⁴, Raed Alhusayen⁵, J. Michael Paterson⁶, Willemina Campbell⁷, Karen Tu⁴, Sasha Bernatsky⁸, Dafna Gladman⁹ and Lihi Eder¹⁰, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³ICES, Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, ⁶ICES, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, University of Toronto, Toronto, ON, Canada, ⁸The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ⁹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁰Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Several studies have consistently demonstrated that psoriasis is associated with an increased risk of mortality compared to the general population. However, the excess risk…
Abstract Number: 1862 • ACR Convergence 2020
Genetic Influences on Occurrence of Axial Spondyloarthritis (axSpA) in First-degree Relatives During a Prospective Study Lasting 35 Years
Muhammad Khan¹, Sjef van der Linden², Peter Villiger³, Zhixiu Li⁴, Mohammad Khan⁵, Heinz Baumberger⁶, Hermine Zandwijk⁷ and Matthew Brown⁸, ¹Case Western Reserve University, Cleveland OH, Westlake, OH, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ³Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁴Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁵Kent State University, Kent, OH, ⁶Retired, Flims, Tajikistan, ⁷Retired, Mortroux, Belgium, ⁸Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom
Background/Purpose: To investigate the recurrence rate (RR) of ankylosing spondylitis (AS) over a lifespan, probands with clinically diagnosed AS and their first-degree relatives (FDRs) were…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].